: [58][59][60][61][62][63][64][65][66] 1985). However, it was necessary to investigate whether this fragment also had the ability to ipduce the production of neutralizing antibodies. Upon immunization of mice, the bovine serum albumin-conjugated 14,000-molecularweight fragment, the unconjugated 14,000-molecular-weight fragment, and the native glycoprotein all induced a similar neutralizing antibody response, albeit to a lesser extent than did the infectious, whole virus. In addition, immuno-blot enzyme-linked immunosorbent assay analysis of the reactivity of anti-peptide serum versus anti-glycoprotein serum with the glycoprotein was very comparable. These results suggest that the 14,000-molecular-weight fragment may represent not only a biologically active region but also an immunodominant area of the glycoprotein.
The major neutralizing antigen of bovine rotavirus (BRV) is an outer surface glycoprotein with an approximate molecular weight of 38,200 in its unreduced form and 41,900 in its reduced form (5, 9) . Several studies have indicated that the presence of disulfide bridges within this molecule is an important feature with respect to its ability to induce a good neutralizing antibody response (1, 9).
A more detailed characterization of the major rotavirus glycoprotein has been achieved by using a variety of monoclonal antibodies (3, 11, 12) . Recently, an epitope located on a 14,000-molecular-weight fragment (14K fragment) of the BRV glycoprotein was identified and found to be involved in neutralization and cell attachment (9) . However, this peptide was antigenic only in its unreduced conformation. To determine its immunogenic potential, the unreduced peptide fragment, derived from infectious virus particles, was injected into animals in a bovine serum albumin (BSA)-conjugated form and an unconjugated form. The resulting antibody responses were compared with those inducd by infectious double-shelled BRV and the purified unreduced form of the glycoprotein. A further experiment was performed to determine whether the peptide could prime an immune response to infecious BRV in the event that a neutralizing antibody response could not be induced by using the peptide alone.
To prepare the various antigens to be used for immunization, BRV (isolate C486, subclone 13) (7) was propagated in MA-104 cells and purified by centrifugation as described previously (9) . One milligram of purified double-shelled virus was then fractionated on a 10% preparative polyacrylamide gel. The 38.2K glycoprotein was localized in the gel by staining side strips of the gel with Coomassie blue. To extract the glycoprotein, gel strips were subjected to electroelution under conditions previously described (9 Further localization of the 14K peptide was achieved by using the molecular weight markers. The peptide fragment was then electroeluted from the gel slices, as previously described (9) , and a protein determination was performed. The authenticity and purity of the peptide were confirmed by examination of its profile on polyacrylamide gels and by its reaction with monoclonal antibodies from hybridoma 11D12-6 (Fig. 1, lane C) . The electroeluted 14K peptide was then lyophilized and a portion of the preparation was conjugated to BSA as follows. One milligram of peptide was first dissolved in 125 ,l of 0.1 M phosphate-buffered saline (pH 7.4). The BSA solution was prepared by dissolving 1.25 mg of BSA in 600 pAl of 0.1 M phosphate-buffered saline and adding dropwise 250 ,ul of a 2.5 M gluteraldehyde solution and the peptide solution consecutively over 15 min. The reaction mixture was gently agitated for 24 h at room temperature and then dialyzed extensively against sterile distilled water. Lyophilization of the conjugated peptide yielded a pinkish powder which was stored in dessicant at
Once all the antigens were prepared, groups of 10 mice (Charles River, Wilmington, Mass.) were immunized with the unconjugated peptide, the BSA-conjugated peptide, the infectious double-shelled virus, or the purified glycoprotein by the protocol outlined in Table 1 . The quantities of antigen to be administered were determined on an equimolar basis. Antibody responses to the different antigens were characterized by enzyme-linked immunosorbent assay (ELISA) and immunoblot ELISA with BRV (isolate C486, subclones 12 and 13) as the antigen and by serum neutralization assays (9) .
There was a significant antibody response to all the antigens used (Fig. 2, upper panel) (9) . Lane D illustrates the purified 14K peptide fragment in a silver-stained polyacrylamide gel.
good antibody response. This may be due to the large size of the peptide fragment, thereby increasing the probability that it contained both B-cell and T-cell determinants (10) .
The animals immunized with the 14K fragments were boosted at 61 days with infectious, double-shelled virus. This was done to investigate the possibility of the fragments priming an immune response. Even though, after analysis of all the sera, the animals did show a good antibody response to the peptides, they also demonstrated an additional, albeit Immunoblot ELISA reactions of sera from selected animals in each group at 37, 51, and 68 days are shown in Fig.  3 . All the sera, except those obtained before immunization and the negative control group (Fig. 3, E) , possessed antibodies to the major glycoprotein. Anti-peptide antibodies, although produced to a 14K peptide prepared from only one of the glycoprotein species present in BRV isolate C486, reacted'with both glycoprotein species present in the protein profile of the parent isolate C486. This was significant since electrophoretypic analysis of the genomic RNA from the two subclones of isolate C486 demonstrated a difference in mobility of the corresponding genes coding for this glycoprotein (7). However, it appears that despite this genetic heterogenicity, the 14K peptide is to a large extent conserved between the two glycoprotein species of BRV isolate C486 subclones 12 and 13. Another interesting observation was the similar intensity displayed by the reaction of the glycoprotein species with anti-peptide antibodies, suggesting that the 14K peptide may represent an immunodominant region of the glycoprotein.
In addition, all the sera including prebleeds and negative controls produced antibodies to a 92K protein, which has the same molecular weight as a minor BRV inner shell protein.
There are several possible explanations for this phenomenon. (i) The mice had a previous rotavirus infection. The mouse rotavirus in this situation would only be crossreactive with the 92K protein of BRV isolate C486. ( ii) The 92K protein is "sticky." Skim milk was used as a blocker of nonspecific sites (during the immunoblot 1-LISA procedure) instead of BSA or gelatin, which are more adhesive, and this may have enabled the 92K protein to remain somewhat exposed. Unfortunately, there was not enough mouse serum to repeat this experiment with alternative blockers; however, anti-glycoprotein serum obtained from rabbits did not give a visible reaction with the 92K protein even when skim milk was used (data not shown). This suggests that the reaction of mouse serum with the 92K protein is inherent in the serum and may account for the presence of anti-ro'tavirus antibodies in the control group (Fig. 2, lane E) .
As shown in this study and in other studies with different viruses, only antibodies to sites representing important biological functions can neutralize virus infectivity. This consideration is, of course, the basis for designing synthetic vaccines. By first searching for such critical sites on the rotavirus glycoprotein, by using monoclonal antibodie$ as probes, we have identified a 14K fragment which possesses the site for virus attachment and neutralization (9) . The antigenic determinants on this peptide appear to represent conformation-dependent antigenic sites (9), posing a difficult immunochemical problem with respect to synthesis of an effective immunogen; especially if these sites are discontinuous. However, this situation is not without precedent, as evidenced by the tick-borne encephalitis virus antigens (4). One approach which has been used to construct such immunogens employs surface simulation synthesis. In this concept, the spatially-adjacenf residues of a protein binding site are linked directly into a single peptide that does not exist in the protein but mimics a surface region of it. This approach is currently under investigation for the rotavirus peptide discussed in this paper. In addition, potential conformational sites within this peptide, which fulfill the criteria of hydrophilicity, the presence of proline residues, size, and charge, are being synthesized and tested for this efficacy as immunogens. 
